The biotech giant is developing a single-shot product that could protect against COVID-19,flu and other respiratory viruses.
Pfizer and Moderna have produced vaccines for children as young as six months. Moderna next plans to study its shots for babies as young as three months.
It’s the global vaccine maker that has delivered huge returns for early backers,but can Moderna continue its growth in a post-COVID world?
Jorge Gomez stepped down just one day after starting his new job,pocketing $1 million in severance pay as he became the latest top executive to leave the COVID-19 vaccine maker.
The vaccine maker said it will ask US regulators to authorise its COVID-19 vaccine for children younger than 6 years old.
Labor and the Coalition will put competing industry plans to voters on Thursday in a contrast on local manufacturing ahead of the federal election campaign.
The US biotech is pushing on with plans to work on combined COVID/flu shots and other vaccines in Australia,with local boss Michael Azrak flagging it will need “quite a number of[local] science grads and PhDs”.
About 34,000 people have contracted the virus in NSW in the past two weeks - almost twice the total number of cases reported during Victoria’s second wave - upending Christmas plans and forcing tens of thousands into isolation.
The company still plans to develop a vaccine specifically to protect against Omicron,which it hopes to advance into clinical trials early next year.
The global pharmaceutical company beat a dozen other businesses and organisations,including Australia’s largest vaccine producer,CSL,for federal and state funding to set up an mRNA vaccine manufacturing facility in Victoria.
The federal government has done a deal with Moderna and the Victorian government to produce mRNA vaccines in Australia from 2024.